allAfrica.com on MSN8h
Africa: A Jab That Could Protect Against HIV for a Year At a Time, and Other Highlights From Major ConferenceA single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
Zacks.com on MSN23h
GILD Stock Down on Report of Cut in HIV Prevention SpendingGilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...
Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
The CDC budget cuts could pose headwinds for HIV drugmakers like Gilead and Merck but are unlikely to severely cripple their ...
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the ...
£35 means we can empower more people living with HIV to challenge stigma with our information workshops, videos and broadcasts. As Gilead Sciences prepares to launch twice-yearly lenacapavir ...
Oppenheimer notes that Gilead (GILD) shares are weak today following reports from multiple media outlets that the Health and Human Services department is mulling cuts to federal HIV prevention funding ...
Health and Me on MSN6d
Yearly Jab For HIV Protection Is Now Almost HereA yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback